Underuse of anticoagulant treatment in patients with atrial fibrillation [4];Infrautilización del tratamineto anticoagulante en pacientes con fibrilación auricular

Medicina Clinica

Volumn 119, Issue 16, 2002, Pages 638-

  García, Amaya ^a   Marín, Francisco ^a   Arrarte, Vicente ^a   Sogorb, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG USE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LETTER; PREVALENCE; RISK FACTOR; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; VALVULAR HEART DISEASE; AGE; CHRONIC DISEASE; ECHOCARDIOGRAPHY; FEMALE; MALE; NOTE; PROTHROMBIN TIME;

AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; PROTHROMBIN TIME;

EID: 0037048846     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)73523-9     Document Type: Letter

References (10)

1. Bertomeu Martínez V, Morillas Blasco PJ, González Juanatey JR, Alegría Ezquerra E, García Acuña JM, Maqueda I, et al. Empleo de fármacos antitrombóticos en pacientes hipertensos con fibrilación auricular crónica. Estudio CARDIOTENS 99. Med Clin (Barc) 2002;118:327-31.
2. Berjón J, Olaz F, De los Arcos E. Epidemiología, factores de riesgo y patogenia de ia fibrilación auricular y del flutter auricular. Rev Esp Cardiol 1996;49 (Supl 2):1-7.
3. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987; 147:1561-4.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised trials. Arch Intern Med 1994;154: 1449-57.
6. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-5.
7. Falcó Ferrer V, Len Abad O, Iglesias Sáez D, Pérez Vega C, Reina D, Roselló J, et al. Análisis de los factores asociados a la indicación de tratamiento anticoagulante en la fibrilacin auricular crónica. Estudio prospectivo de 170 pacientes ingresados en un servicio de Medicina Interna. Rev Clin Esp 2000;200:203-7.
8. Aloy-Duch A, Cuenca-Luque R, Rollán Serrano E, Casanova Sandoval JM. Utilización de fármacos antitrombóticos en pacientes con fibrilación auricular crónica en un área sanitaria comarcal. Med Clin (Barc) 1999;112:454-6.
9. García A, Sánchez B, Marín F, Roldán V, Marco P. Diurnal variation in the intensity of anticoagulation in atrial fibrillation. Stroke 2002;33:322-3.
10. Rochon PA, Katz JN, Morrow LA, McGliney-Berroth R, Ahlquist MM. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care 1996;34:1093-101.